iX Biopharma 1Q27 net loss widens to $3.33 million year-on-year

PUBT · 1d ago
iX Biopharma 1Q27 net loss widens to $3.33 million year-on-year
  • iX Biopharma's net loss widened to SGD 3.33 million in the quarter ended September 30, 2026, versus a year earlier.
  • Revenue rose 69% year over year to SGD 2.71 million, with the Wafermine development program contributing 65% of the total.
  • General and administrative expenses more than doubled year over year to SGD 2.94 million, primarily due to compensation, patent-related and restructuring costs.
  • The group moved freeze-drying equipment from Australia to Nevada to support US supply, temporarily reducing production capacity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: UB9F4NGX2VCE63H8) on November 11, 2026, and is solely responsible for the information contained therein.